Compare KEQU & ONCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KEQU | ONCY |
|---|---|---|
| Founded | 1906 | 1998 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Pharmaceuticals and Biotechnology |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 110.9M | 107.3M |
| IPO Year | 1995 | 2002 |
| Metric | KEQU | ONCY |
|---|---|---|
| Price | $35.62 | $0.80 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $7.33 |
| AVG Volume (30 Days) | 4.4K | ★ 1.5M |
| Earning Date | 03-11-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 3.22 | N/A |
| Revenue | ★ $138,558,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $2,505.00 |
| P/E Ratio | $11.18 | ★ N/A |
| Revenue Growth | ★ 7.72 | N/A |
| 52 Week Low | $33.27 | $0.77 |
| 52 Week High | $60.89 | $1.51 |
| Indicator | KEQU | ONCY |
|---|---|---|
| Relative Strength Index (RSI) | 48.43 | 41.24 |
| Support Level | $35.15 | N/A |
| Resistance Level | $41.25 | $1.06 |
| Average True Range (ATR) | 0.99 | 0.07 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 28.20 | 6.19 |
Kewaunee Scientific Corp is a designer and manufacturer of technical furniture products for industries investing in spaces where discovery occurs, typically in laboratories. It serves in end-use markets that are all commercial, Life sciences, pharma, education, government and military research, etc. The company operates through two segments: The domestic segment designs manufactures and installs scientific and technical furniture, including steel and wood laboratory cabinetry, fume hoods, laminate casework, flexible systems, and Others; The International segment provides facility design, engineering, construction, and project management from the planning stage through the testing and commissioning of laboratories. It generates the majority of its revenue from the Domestic business segment.
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer, among others.